医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Foldax, Inc. Signs Manufacturing Agreement with Dolphin Life Science India LLP to Expedite Upcoming Commercial Availability

2024年02月27日 PM07:00
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

Foldax® Inc., a pioneer in the development of innovative, polymer heart valves, today announced a manufacturing agreement with Dolphin Life Science India LLP to enable in-country manufacturing of the TRIA™ polymer mitral surgical heart valve outside of the U.S. for the first time.

The TRIA mitral valve is designed specifically to accommodate the anatomy and pressures of the mitral position. It combines the company’s proprietary polymer – LifePolymer™ – with an innovative valve design intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants.

The novel LifePolymer material and computer-designed valve help to democratize the manufacturing process, minimizing the people and processes associated with animal-based tissue valve manufacturing, enabling manufacturing in any location, and improving product variability, precision, repeatability, and quality.

“Our collaboration with Dolphin Life Science India LLP represents a pivotal move toward expediting the commercial release of the TRIA valve in our first targeted commercial region of India,” said Ryan Stanfield, Vice President of Engineering and Operations with Foldax, Inc.

“We are honored to collaborate with Foldax to bring the TRIA valve manufacturing capability to India, with the intent of making a positive difference in the lives of millions of rheumatic heart disease (RHD) patients who can benefit from this novel polymer valve,” said Mukesh Chovatiya, Managing Director of Dolphin Life Science India.

Dr. Kaushal Pandey, an investigator in the Company’s recent India clinical trial of the TRIA valve, who believes it to be the fastest-enrolling clinical trial for any surgical mitral valve, commented, “We have a pressing need in India for alternatives to tissue and mechanical valves, as current commercial offerings often fall short in durability and patient acceptance. I am encouraged to see the Company’s progress in getting one step closer to making this exciting heart valve available to Indian patients who critically need it.”

The TRIA heart valve and LifePolymer technology are considered investigational and are not available for commercial sale in the U.S. or any other region.

Dolphin Life Science India LLP is an expert in manufacturing medical devices. The company is registered with India’s regulatory bodies, the Drugs Controller General of India (DCGI), and the Central Drugs Standard Control Organization (CDSCO).

About Foldax

Foldax Inc. is a medical device company committed to reinventing every aspect of the heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime addressing historical tradeoffs.

To learn more about Foldax, visit www.foldax.com.

Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227774410/en/

CONTACT

MEDIA CONTACT:

Michelle McAdam, Chronic Communications, Inc.

michelle@chronic-comm.com

(310) 902-1274

同じカテゴリーの記事 

  • PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
  • Technology Holdings就领先的医疗技术产品设计和工程咨询公司Design + Industry战略性售予Capgemini的事宜向其提供咨询服务
  • Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
  • Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris
  • Southeast Asian Countries Lead in Positive Experiences